AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
The United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera (Nasdaq: ABCL), rejecting Berkeley Lights’ challenge to the validity of AbCellera’s U.S. Patent No. 10,087,408.
This patent pertains to microfluidic devices for cell culture and monitoring. Berkeley Lights previously filed multiple petitions with the PTAB, all of which have now been rejected. AbCellera expressed satisfaction with the decision and plans to proceed with its pending patent infringement lawsuit against Berkeley Lights. This outcome reinforces the strength of AbCellera's intellectual property portfolio.
- PTAB ruling strengthens the validity of AbCellera's microfluidic cell culture patent.
- All claims of U.S. Patent No. 10,087,408 confirmed as valid, enhancing AbCellera's intellectual property position.
- AbCellera intends to resume its infringement case against Berkeley Lights, potentially leading to favorable legal outcomes.
- None.
PTAB rejects third request by Berkeley Lights for invalidation of AbCellera’s
The IPR proceeding stems from AbCellera and the
“We are pleased with the PTAB’s decision, which reinforces the validity and strength of our microfluidic cell culture system patent claims,” said
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005918/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What did the PTAB decide regarding AbCellera's patent?
What is the significance of the PTAB ruling for AbCellera (ABCL)?
How does the ruling affect AbCellera's legal actions?
What technology does U.S. Patent No. 10,087,408 cover?